We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Boston Therapeutics Wins FDA Approval to File an ANDA for Pazamet to Treat Diabetes
Boston Therapeutics Wins FDA Approval to File an ANDA for Pazamet to Treat Diabetes
October 4, 2012
Boston Therapeutics announced the FDAhas approved the petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of the diabetes drug metforminhydrochloride. MENA FN
